Thrombotic Thrombocytopenic Purpura - Product Development Milestones
Featured News & Press Releases
Dec 21, 2017: Ablynx Announces Positive Data From Its Japanese Ethno-Bridging Study Of Caplacizumab
Dec 12, 2017: Ablynx Reports Additional Clinically Important Benefits of Caplacizumab From its Phase III Hercules Study in Acquired TTP
Dec 07, 2017: Ablynx Will Host a Webcast to Discuss Additional Data From its Phase III Hercules Study of Caplacizumab in Acquired TTP Following Ash Late-Breaking Data Presentation
Nov 21, 2017: Results From the Phase III Hercules Study of Caplacizumab for the Treatment of Acquired TTP Selected For Presentation In The Late-Breaking Abstracts Session at The 2017 Ash Annual Meeting
Oct 16, 2017: Ablynx Establishes Subsidiary in the USA and Appoints a General Manager
Oct 02, 2017: Ablynx Announces Positive Topline Results From The Phase III Hercules Study Of Caplacizumab For The Treatment Of Acquired TTP
Sep 14, 2017: Engineered Therapy for Blood Clotting Disorder Shows Early Promise
Jul 26, 2017: Ablynx Receives Fast Track Designation From The FDA For Caplacizumab For The Treatment Of Acquired TTP
Jun 26, 2017: Ablynx Initiates a Single And Multiple Dose Phase I Study of Caplacizumab in Healthy Japanese Subjects
May 02, 2017: Ablynx Completes Patient Recruitment in its Phase III Hercules Study of Caplacizumab for the Treatment of aTTP
Mar 22, 2017: Shire receives FDA Fast Track designation for recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura
Feb 06, 2017: Ablynx Submits a Marketing Authorisation Application to the European Medicines Agency for Caplacizumab, Its Anti-vWF Nanobody, for the Treatment of aTTP
Oct 10, 2016: Ablynx Initiates a Phase III Follow-Up Study of Its First-In-Class Wholly-Owned Anti-Vwf Nanobody, Caplacizumab, For the Treatment of Acquired TTP
Sep 29, 2016: Ablynx First-In-Class Wholly-Owned Anti-vWF Nanobody, Caplacizumab, May Have The Potential To Reduce Morbidity And Mortality Associated With Acquired TTP
May 26, 2016: Ablynx To Present A Post-Hoc Analysis Of The Phase II Titan Study With Caplacizumab In Acquired Ttp Patients At The 21St Congress Of The European Hematology Association
Expert Panel Validation
List of Tables
Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Thrombotic Thrombocytopenic Purpura - Pipeline by Ablynx NV, H1 2018
Thrombotic Thrombocytopenic Purpura - Pipeline by Kaketsuken, H1 2018
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2018, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.
Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)
Reasons to buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.